Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
ebay u.k.
Popular Articles
Cellulite Treatment

Sylvester Breast Cancer Researchers Win Prestigious Department Of Defense Grant To Expand Study Of African-American Women
Breast cancer researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have been awarded a prestigious Department of Defense Synergistic Idea Award, one of just 12 such grants in the United States. The $725,000 research grant over two years will allow Lisa Baumbach, Ph.D., associate professor of pediatrics at the Miller School, and Mark Pegram, M.D., professor of medicine and associate director for clinical and translational research at the Braman Family Breast Cancer Institute at Sylvester, to expand their work examining the genetic differences found in African-American breast cancer patients.
generic viagra online
First Evidence That Monkeys Wonder What Might Have Been
Monkeys playing a game similar to "Let"s Make A Deal" have revealed that their brains register missed opportunities and learn from their mistakes.
News of the day
Washington, D.C., Officials Expand STI Testing Program To All Public High Schools
Washington, D.C., officials are planning to make testing for sexually transmitted infections available at all public high schools in the coming school year, adding D.C. to a growing list of cities that test students for STIs, the Washington Post reports. All 50 states and the district allow minors older than age 12 to be tested for STIs without parental consent.The new program requires all students to attend a lecture about STIs, after which they are escorted into restroom areas in groups of 15 to 20. They are then given paper bags with urine collection cups and go into the stalls, at which point they can decide whether to provide a sample. All students return the paper bags, regardless of whether they provided samples. Students give a password and can call a week later to receive their confidential results and, if necessary, treatment at the school or an STI clinic, which is paid for by the city. The district first offered the program two years ago at two charter schools, and eight high schools were included during the past school year.A 2007 study by the D.C. public school system found that 60% of high school students and 30% of middle school students reported having sex. According to the study, 20% of high school students reported having sex with four or more partners and 12% of middle school students reported having three or more partners.According to the D.C. Department of Health, the program at eight high schools last year found that 13% of 3,000 students tested positive for an STI, most commonly chlamydia or gonorrhea. Fifty percent of the chlamydia and gonorrhea cases in the district are among teenagers.According to the D.C. Appleseed Center for Law and Justice, the new program is an important step toward curbing the district"s HIV/AIDS rate, which is among the highest in the U.S. Walter Smith, executive director of D.C. Appleseed, said, "If 13% of these students are testing positive for [STIs], those same kids could get HIV," adding, "A lot needs to be done to get the message out to the schools, ... and this very high [STI] rate is an indication that what we"ve been doing is not effective" (Fears/Hernandez, Washington Post, 8/5).
Diagnostics

The Lives Of Pancreatic Cancer Patients Prolonged By New Drug Candidate

Every year, 42,000 Americans are diagnosed with pancreatic cancer. Few live very long, and less than 5% are still alive five years after diagnosis. There"s new hope, though, from the lab of Prof. Yoel Kloog, dean of TAU"s Faculty of Life Sciences. His drug compound Salirasib has shown positive results against pancreatic cancer and recently passed Phase I/II clinical trials. The drug, given in combination with gemcitabine, the standard drug used to combat pancreatic cancer, almost doubled the life expectancy of those who received it. "In our study, the mean survival of pancreatic cancer patients was 10.8 months - better by far than the 6.2 months with gemcitabine alone," says Prof. Kloog, who recently presented the results to a meeting of the American Society of Clinical Oncology. His basic research offers the promise of a weapon to attack a broader range of mankind"s most prevalent diseases, including lung, prostate and breast cancers as well as diabetes. Blocking the Ras protein Salirasib works by inhibiting a protein called Ras, which is known to be abnormally activated in one-third of human cancers. In cancer of the pancreas, mutant forms of Ras are found in up to 90% of all tumors. Salirasib"s basic component, FTS, works to block the formation of cancer-promoting Ras nanoclusters, thus blocking a cascade of biochemical signals known as the "Ras signaling pathway" that allow Ras to wreak havoc on the body. Early in the 1990s, many drug developers chased after a mechanism to inhibit Ras by targeting enzymes that modify it, but they were unsuccessful. "The major developers gave up, claiming Ras is not targetable," says Prof. Kloog, "but our concept takes a different approach. Now that we"ve shown it works in human subjects, I am definitely excited - no doubt about it." Prof. Kloog developed the Ras antagonist more than 15 years ago. No toxic side effects In the latest study, researchers tested for both toxicity and effectiveness. They gave 19 patients with advanced pancreatic cancer daily doses of salirasib along with a standard gemcitabine regimen. Salirasib was well tolerated by the patients, and they surpassed on average the number of months they would have lived on gentamiacine alone. There were no toxic side effects, such as heart or lung ailments. Tumor biopsies showed a significant reduction in Ras levels, suggesting that the drug is inhibiting the action of Ras in the tumor itself. For this study, Salirasib was licensed by Concordia Pharmaceuticals, which collaborated with the Memorial Sloan Kettering Cancer Center, Johns Hopkins, the M.D. Anderson Cancer Center and other institutes in the United States. If Phase II/III trials are successful, Prof. Kloog"s drug will be the first successful Ras antagonist known to medical science. Salirabib could be medically available in as little as two years. George Hunka American Friends of Tel Aviv University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009